Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Johnson & Johnson (

3 Solid Pharma Stocks for a Healthy Year-End Portfolio

The pharma industry is transforming due to the rapid adoption of AI and global healthcare spending, fostering innovation and patient care advancements. Therefore, fundamentally sound pharma stocks Eli Lilly (LLY), Wave Life Sciences (WVE) and Johnson & Johnson (JNJ) might be worth adding to boost your portfolio. Continue reading.

StockNews.com

A CEO contender left Johnson & Johnson. Was she penalized for saying she wanted the job?

The exit of a Johnson & Johnson exec raises an age-old question about women's ambition.

Fortune

His dad worked on the factory floor at Johnson & Johnson. Now he’s the CFO

Joe Wolk, with J&J for over 25 years, talks about his path and the company's focus on innovation.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Breakthrough antidepressants with fewer side effects could help millions of Americans. Here's what the future of treatment may look like

As Americans are increasingly reaching for pharmaceutical solutions for depression—about one in eight U.S. adults takes antidepressants—scientists have been innovating novel treatments for it.

Fortune

Should You Invest in Johnson & Johnson (JNJ) Following Q3 Results

Johnson & Johnson’s (JNJ) third-quarter results impressed investors, as its earnings and revenue beat Wall Street estimates. Should investors consider investing in the stock following the solid third-quarter results? Read on to learn my view….

StockNews.com

Johnson & Johnson Raises Outlook As The Health Care Bellwether Beats Views

Johnson & Johnson beat third-quarter forecasts Tuesday and raised its outlook for the year. JNJ stock skidded lower after the open.

Investors Business Daily

3 Dividend Aristocrats to Defend Your Portfolio in Q4

In the midst of economic uncertainty, look to the likes of Procter & Gamble, Coca-Cola, and Johnson & Johnson as steadfast investment options, offering relative stability and reliable income for Q4 2023 and beyond.

Barchart

Read news from The Economist, FT, and more,
with one subscription

How big companies from EY to Johnson & Johnson are learning to master AI prompts

Embracing AI is the easy part—firms have already moved on to harder parts like making AI actually work for their business.

Fortune

Johnson & Johnson (JNJ) vs. Madrigal Pharmaceuticals (MDGL): Which Pharma Stock Is a Worthier October Investment?

With an aging population worldwide, the growing prevalence of chronic diseases, new drug discoveries and rapid digital advancements, the outlook for the pharmaceutical sector remains optimistic. Pharma stocks Johnson & Johnson (JNJ) and Madrigal Pharmaceuticals (MDGL) will likely benefit from the industry’s bright prospects. But which of these stocks is…

StockNews.com

Generative AI is top of mind for all types of leaders, from Treasury Secretary Janet Yellen to J&J CEO Joaquin Duato

This week’s episode of Fortune‘s Leadership Next podcast features conversations from the Fortune CEO Initiative conference.

Fortune

Three Stocks To Help You Through the Financial Roller Coaster!

The Middle East is back in focus as tensions broke. But, what can investors own to weather the storm?

Barchart

Travis Kelce shakes off Aaron Rodgers dig: ‘I’m fully comfortable with him calling me Mr. Pfizer’

Mr. Pfizer and his mustache are doing just fine.

USA Today Sports Media Group

Chiefs’ Travis Kelce Responds to Aaron Rodgers’s ‘Mr. Pfizer’ Jab

“Who knew I’d get into the vax wars with Aaron Rodgers, man?”

Sports Illustrated

Aaron Rodgers oddly called Travis Kelce ‘Mr. Pfizer’ despite playing for the Johnson & Johnson heir

Aaron Rodgers can be such a dork, man.

USA Today Sports Media Group

Get all your
news in one place.

100’s of premium titles.
One news app.

Fortune

In rare interview, J&J CEO Joaquin Duato opens up about Baby Powder cancer lawsuits and the future of Kenvue

J&J CEO Joaquin Duato's interview on Baby Powder cancer lawsuits, Kenvue, and the COVID vaccine.

Barchart

Johnson & Johnson Stock Looks Like Good Value Now

Johnson & Johnson stock (JNJ) recently spun off its consumer Kenvue business, which trades separately under the symbol KVUE. However, JNJ stock has dipped and now looks like good value.

Barchart

Protect Your Returns With These 3 Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Barchart

Protect Your Returns With These Three Dividend Kings!

Looking for long-term income and stability? Here's 3 dividend kings you won't want to miss!

Get all your
news in one place.

100’s of premium titles.
One news app.

AAP

Lawyers lose in better deal for pelvic mesh victims

A law firm that ran two class actions for women harmed by pelvic mesh implants will lose out on a $38.5 million cut of $405 million in settlement funds.

Fortune

This J&J exec sold Tylenol and Listerine. Now she runs its $27B medtech business

Ashley McEvoy pivoted from over-the-counter products to medical devices.

The Independent UK

Johnson & Johnson is getting rid of its script logo after more than 130 years

Johnson & Johnson is signing off on a new logo, more than 130 years after creating the old one

Reason

Fake Sudafed Is Bullshit, Just As You Suspected

Legal restrictions on pseudoephedrine have not reduced meth use, but they have driven people with colds or allergies toward substitutes that seem to be completely ineffective.

WEKU

The FDA asked advisers to take another look at phenylephrine, which became the main drug in over-the-counter decongestants when medicines with an older ingredient were moved behind pharmacy counters.

Chicago Sun-Times

Advisers to the Food and Drug Administration voted unanimously on Tuesday against the effectiveness of the key drug phenylephrine found in popular versions of Sudafed, Dayquil and other medications stocked on store shelves.

The Independent UK

Government advisers say the leading decongestant used by millions of Americans to treat nasal congestion doesn't actually work

1 … 4 5 6 7

People

Dipanjan BanchurSince

722 stories

Pat McAfee

619 stories

Mangeet Kaur BounsMangeet

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.